Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, U4 small nuclear 18, pseudogene** (RNU4-18P) is classified as a *pseudogene* and is catalogued in gene databases such as GeneCards[1]. Pseudogenes are typically disabled genomic DNA sequences derived from functional genes but are not themselves functional; they do not code for functional proteins or RNAs and generally lack biological activity. There is no evidence in authoritative sources that RNU4-18P acts as a therapeutic or functional molecular target, nor are there any reported associations with disease, drugs, or physiological function. Instead, RNU4-18P is simply listed as a disabled or nonfunctional member of the **U4 small nuclear RNA** family, with no known role in cellular or disease processes[1]. **Key clarification:** The **functional gene** in the U4 small nuclear RNA family that has known biological and clinical significance is **RNU4-2** (RNA, U4 small nuclear 2), which is implicated in neurodevelopmental disorders[2][3][5][7]. **RNU4-18P** is not known to be involved in these processes and should not be used as a synonym for RNU4-2. **Summary of assessment:** - RNU4-18P is a *nonfunctional pseudogene* with no established molecular or therapeutic importance[1]. - If your intention was to refer to the **functional U4 small nuclear RNA** gene, you likely meant **RNU4-2**, not RNU4-18P. - No evidence supports its role as a biological or clinical target, nor any disease association, drug interaction, or mechanism of action. - It is **incorrect to treat RNU4-18P as an active target or receptor**. If you need data for the functional U4 snRNA gene, see entries for **RNU4-2** instead. **References for functional relevance:** - RNU4-18P: nonfunctional pseudogene with no active role[1]. - RNU4-2: functional snRNA, mutations linked to ReNU syndrome and spliceosomal function[2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 18, pseudogene (RNU4-18P).